Cypress Bioscience, Inc. – EXECUTIVE BONUSES 2009 There Are Two 2009 Corporate Objectives That Could Trigger Bonus Payments Under the 2009 Bonus Plan: (April 14th, 2009)
1) Complete a major corporate event, such as an in-license or product acquisition (50%) 2) Achieve commercial objectives established for Savella and the Avise product line (50%)
Cypress Bioscience, Inc. – Amended and Restated Employment Agreement (March 16th, 2009)
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this Agreement) is made and entered into effective as of this 31st day of December, 2008 by and between Cypress Bioscience, Inc., a Delaware corporation (the Company) and Denise Wheeler (the Employee).
Cypress Bioscience, Inc. – Retention Agreement (February 25th, 2008)
This RETENTION AGREEMENT (this Agreement) is made on and as of February 23, 2008, by and among (the Key Employee), Proprius, Inc. (doing business in California as Proprius Pharmaceuticals, Inc.), a Delaware corporation (the Company), and Cypress Bioscience, Inc., a Delaware corporation (Parent).
Cypress Bioscience, Inc. – EXECUTIVE BONUSES 2008 There Are Two 2008 Corporate Objectives (January 28th, 2008)
Cypress Bioscience, Inc. – There Is a Primary 2007 Milnacipran Related Corporate Objective: Statistical Significance Achieved on MD-02, Milnacipran Phase III Trial. (100%) (October 31st, 2006)
A 100% weighting percentage is assigned to this objective. The bonus payable is equal to the weighting percentage multiplied by the 'Target Bonus' amount as defined below. The bonus is payable upon achievement of the objective (top-line data announcement).